Orchid Pharma's Amalgamation with Dhanuka Laboratories Approved
Orchid Pharma Limited's amalgamation with Dhanuka Laboratories Limited has been approved by the NCLT, Chennai. The Appointed Date is April 01, 2024. The merger aims to create a larger entity with potential sales turnover of ₹1400-1500 crore. Orchid Pharma will issue 161 shares for every 5 shares of Dhanuka Laboratories.
The amalgamation of two companies is a significant corporate event that will fundamentally alter the structure and scale of Orchid Pharma, leading to substantial changes in operations, market position, and financial metrics.
The NCLT's approval of the amalgamation scheme is a positive development for Orchid Pharma, paving the way for its merger with Dhanuka Laboratories. This is expected to create a larger, more efficient entity with enhanced market presence and financial strength.
The National Company Law Tribunal (NCLT), Chennai Bench, has approved the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited. The order, pronounced on June 05, 2026, and made available on June 11, 2026, allows the merger petition. The Appointed Date for the scheme is April 01, 2024, and it will become effective upon completion of the outlined steps. The tribunal noted the absence of material objections from statutory authorities and compliance with requisite procedures. The amalgamation aims to create a larger entity with a potential sales turnover of ₹1400-1500 crore and EBITDA of ₹200-250 crore, enhancing efficiency, market presence, and shareholder value. The scheme involves the issuance of 161 equity shares of Orchid Pharma (face value ₹10) for every 5 equity shares of Dhanuka Laboratories (face value ₹100). The Income Tax Department reserved its right to proceed under the Income Tax Act, 1961, and the Official Liquidator sought undertakings regarding employee protection and record date fixation.
The NCLT's order stipulates that all properties, rights, and liabilities of Dhanuka Laboratories will transfer to Orchid Pharma. The effective date will be determined once the certified order copy is filed with the Registrar of Companies. The tribunal clarified that the sanction does not grant exemption from stamp duty, taxes, or other applicable charges. The amalgamation is expected to streamline the group structure, reduce administrative costs, and improve the competitive position of the combined entity.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under amalgamation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.